Company intelligence / Profile preview

RetInSight

Ownership: Private
Development stage: Commercial

Overview

RetInSight’s MDR-certified AI software solutions are commercially available in Europe and used in routine clinical practice as well as pharmaceutical trials. Their tools enable precise diagnosis and monitoring of major retinal diseases using OCT imaging. The company’s technology has been validated through academic collaborations and commercial deployments across Europe.

Therapeutic areas: Ophthalmology
Modalities: DeviceSoftware
Industry: Medical Imaging

Partnerships

Kilabs Srl (exclusive distribution agreement for Italy)Academic collaborations with Medical University of Vienna and University Eye Hospital WürzburgTopcon Healthcare integration post-acquisition enables broader partnerships via the parent company.

Beyond the preview

Go deeper on RetInSight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RetInSight.

Explore the full profile